← All drugs
Drug · FAERS side-effect profile with label screen

Fluticasone Propionate side effects: what 128,934 FDA adverse event reports show

Fluticasone Propionate · Flovent Diskus · 1,184 reaction terms · 542,225 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Inhaled corticosteroid (ics)

FDA label, Indications wording

Brand names

Flovent Diskus

openFDA label

Who reports

128,934 reports · 52% serious · 6,697 with death outcome · 66% female

openFDA FAERS counts, all years, deduplication not applied

Used for

FLOVENT DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. FLOVENT DISKUS is an inhaled corticosteroid (ICS) indicated for: • Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older.

FDA label, Indications and Usage

What it is

Fluticasone propionate is a trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.

PubChem CID 444036 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 12Reporting / coding artifact 4Not in label — unassessed 23
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal flatulence158174.8
139.5–219.1ROR 175.1 · calibrated p 2e-9 ✓
83.1 EB05 72.8 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=158 · ♀ 100% (drug 66%) · 100% clinicianno trial arm names this drug
Appendicolith12882.6
66.7–102.2ROR 82.7 · calibrated p 6e-7 ✓
54.3 EB05 46.9 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=128 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Drug therapy9972.7
57.3–92.2ROR 72.8 · calibrated p 2e-6 ✓
49.8 EB05 42.1 · IC025 +5.0
3/3 methods agree
Reporting / coding artifactserious n=99 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Analgesic therapy9269.5
54.4–88.8ROR 69.5 · calibrated p 2e-6 ✓
48.2 EB05 40.5 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=92 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Adrenal suppression15636.7
30.9–43.7ROR 36.8 · calibrated p 1e-4 ✓
29.9 EB05 26.2 · IC025 +4.5
3/3 methods agree
Labeled adverse reaction
exact term
serious n=155 · ♀ 45% (drug 66%) · 100% clinicianno trial arm names this drug
Mite allergy11033.7
27.4–41.4ROR 33.7 · calibrated p 2e-4 ✓
27.9 EB05 23.8 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=107 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Overlap syndrome9626.1
21.1–32.4ROR 26.2 · calibrated p 6e-4 ✓
22.5 EB05 19.0 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=96 · ♀ 100% (drug 66%) · 100% clinicianno trial arm names this drug
Female genital tract fistula22123.8
20.7–27.4ROR 23.9 · calibrated p 9e-4 ✓
20.8 EB05 18.6 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=221 · ♀ 100% (drug 66%) · 100% clinicianno trial arm names this drug
Mycotic allergy10523.0
18.8–28.2ROR 23.0 · calibrated p 0.001 ✓
20.2 EB05 17.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=94 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Eosinophilic granulomatosis with polyangiitis24222.0
19.3–25.2ROR 22.1 · calibrated p 0.001 ✓
19.4 EB05 17.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=241 · ♀ 0% (drug 66%)no trial arm names this drug
Chronic kidney disease-mineral and bone disorder12521.3
17.6–25.6ROR 21.3 · calibrated p 0.002 ✓
18.8 EB05 16.2 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=125no trial arm names this drug
Obstructive sleep apnoea syndrome15119.6
16.6–23.2ROR 19.6 · calibrated p 0.002 ✓
17.5 EB05 15.3 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=148no trial arm names this drug
Dust allergy10419.5
15.9–24.0ROR 19.6 · calibrated p 0.002 ✓
17.5 EB05 14.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=95 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Infusion site discharge17017.8
15.2–20.9ROR 17.9 · calibrated p 0.003 ✓
16.1 EB05 14.2 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=122 · 100% consumerno trial arm names this drug
Nephrogenic anaemia41515.7
14.2–17.4ROR 15.8 · calibrated p 0.006 ✓
14.4 EB05 13.3 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=415no trial arm names this drug
Temperature regulation disorder19315.7
13.5–18.2ROR 15.7 · calibrated p 0.006 ✓
14.3 EB05 12.7 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=192 · ♀ 100% (drug 66%) · 100% clinicianno trial arm names this drug
Hyperparathyroidism secondary21615.1
13.1–17.3ROR 15.1 · calibrated p 0.007 ✓
13.8 EB05 12.3 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=215no trial arm names this drug
Radiculopathy21014.0
12.1–16.1ROR 14.0 · calibrated p 0.010 ✓
12.9 EB05 11.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=207 · ♀ 100% (drug 66%)no trial arm names this drug
Infusion site reaction22713.7
12.0–15.7ROR 13.7 · calibrated p 0.010 ✓
12.6 EB05 11.3 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=198 · ♀ 100% (drug 66%)no trial arm names this drug
Rhinalgia21113.5
11.8–15.6ROR 13.5 · calibrated p 0.011 ✓
12.5 EB05 11.1 · IC025 +3.4
3/3 methods agree
Not in label — unassessed100% consumerno trial arm names this drug
Sputum increased15412.7
10.8–15.0ROR 12.7 · calibrated p 0.014 ✓
11.7 EB05 10.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=129no trial arm names this drug
Neuritis10411.7
9.6–14.3ROR 11.7 · calibrated p 0.019 ✓
10.8 EB05 9.1 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=103 · ♀ 0% (drug 66%) · 100% clinicianno trial arm names this drug
Facet joint syndrome21111.6
10.1–13.3ROR 11.6 · calibrated p 0.019 ✓
10.8 EB05 9.6 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=211 · ♀ 100% (drug 66%) · 100% clinicianno trial arm names this drug
Rebound acid hypersecretion20411.5
10.0–13.3ROR 11.5 · calibrated p 0.020 ✓
10.7 EB05 9.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=204no trial arm names this drug
Product package associated injury14711.5
9.7–13.6ROR 11.5 · calibrated p 0.021 ✓
10.7 EB05 9.3 · IC025 +3.1
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Product delivery mechanism issue31711.3
10.1–12.6ROR 11.3 · calibrated p 0.021 ✓
10.5 EB05 9.6 · IC025 +3.2
3/3 methods agree
Reporting / coding artifact86% consumerno trial arm names this drug
Infusion site haemorrhage20911.1
9.7–12.8ROR 11.2 · calibrated p 0.023 ✓
10.4 EB05 9.2 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=123 · 74% consumerno trial arm names this drug
Nasal dryness40311.1
10.0–12.3ROR 11.1 · calibrated p 0.022 ✓
10.4 EB05 9.6 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=81 · 87% consumerno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Serious infection9,6352.02.0–2.1signal
Depression3,3962.01.9–2.0raised
Tendon disorder4061.71.6–1.9raised
Fall / fracture3,8271.61.6–1.7raised
Hyponatraemia8071.61.5–1.8raised
Venous thromboembolism2,1101.61.5–1.7raised
Kidney injury4,1441.51.4–1.5raised
Arrhythmia / qt1,6981.41.4–1.5raised
Anaphylaxis / angioedema1,0501.41.3–1.4raised
Gi bleeding1,5141.31.3–1.4raised
Opportunistic infection1,1221.31.3–1.4raised
Heart failure1,4091.31.2–1.4raised
Anaemia2,3211.31.2–1.3raised
Interstitial lung disease7201.21.1–1.3raised
Hyperglycaemia / diabetes2,3731.11.1–1.2raised
Liver injury1,8931.01.0–1.1no difference

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Fluticasone Propionate (searched FLUTICASONE PROPIONATE).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)10,3241.3
1.3–1.3ROR 1.3 · calibrated p 0.508
1.3 EB05 1.3 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.4no trial arm names this drug
Dyspnoea (shortness of breath)8,6582.5
2.5–2.6ROR 2.6 · calibrated p 0.764
2.5 EB05 2.4 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.8no trial arm names this drug
Fatigue (tiredness)8,5721.8
1.8–1.8ROR 1.9 · calibrated p 0.865
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.2no trial arm names this drug
Headache8,3502.2
2.1–2.2ROR 2.3 · calibrated p 0.920
2.2 EB05 2.1 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.6no trial arm names this drug
Nausea7,4511.5
1.5–1.6ROR 1.6 · calibrated p 0.689
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.0no trial arm names this drug
Pain6,4581.7
1.7–1.8ROR 1.8 · calibrated p 0.800
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.1no trial arm names this drug
Off label use (used outside approved label)6,3721.2
1.2–1.2ROR 1.2 · calibrated p 0.443
1.2 EB05 1.2 · IC025 +0.2Reporting / coding artifactage-adj. PRR 1.2 · serious PRR 1.4no trial arm names this drug
Diarrhoea (diarrhea)6,3661.6
1.6–1.7ROR 1.6 · calibrated p 0.736
1.6 EB05 1.6 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Cough5,7383.4
3.3–3.5ROR 3.5 · calibrated p 0.486
3.3 EB05 3.3 · IC025 +1.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.2 · serious PRR 3.8no trial arm names this drug
Dizziness5,4121.8
1.7–1.8ROR 1.8 · calibrated p 0.835
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.1no trial arm names this drug
Pneumonia (lung infection)5,0112.5
2.5–2.6ROR 2.6 · calibrated p 0.769
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.6 · serious PRR 2.9no trial arm names this drug
Asthma4,7627.2
7.0–7.4ROR 7.4 · calibrated p 0.084
6.9 EB05 6.7 · IC025 +2.7
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 8.0 · serious PRR 8.3no trial arm names this drug
Vomiting4,3981.5
1.5–1.6ROR 1.5 · calibrated p 0.673
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Arthralgia (joint pain)4,2321.7
1.6–1.7ROR 1.7 · calibrated p 0.762
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.1no trial arm names this drug
Rash4,0141.5
1.5–1.6ROR 1.5 · calibrated p 0.658
1.5 EB05 1.5 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Fluticasone Propionate?

In FDA FAERS, the most frequently co-reported reaction terms for Fluticasone Propionate are dyspnoea, fatigue, headache, nausea, pain, diarrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Fluticasone Propionate have an FDA boxed warning?

No. The FDA label retrieved for Fluticasone Propionate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Fluticasone Propionate causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.